Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03090737 · ClinicalTrials.gov registry record · Phase 2
Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 129
- Enrollment target
- 17
- Study locations
NCT03090737 is a Phase 2 study of Non-Small Cell Lung Cancer that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 129 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (80% lower). The trial reports 17 study locations across 13 states.
The verdict
NCT03090737, a Phase 2 study of Non-Small Cell Lung Cancer, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 129 participants
- Enrollment target
- 17
- Study locations
Study Summary
A study to evaluate the safety of Nivolumab in participants with advanced or metastatic non-small cell lung cancer
Conditions Studied
Interventions
- BIOLOGICAL Nivolumab
Study Locations (17)
Ontario
- Local Institution - 0015 - Kingston
- Local Institution - 0014 - Oshawa
- Local Institution - 0001 - Toronto
Other
- Local Institution - 0016 - Tokyo
- Local Institution - 0003 - Craiova
- Local Institution - 0006 - Sector 2
Alabama
- Alabama Oncology - Birmingham
California
- Los Angeles Hematology Oncology Medical Group - Los Angeles
Montana
- St Vincent Frontier Cancer Center - Billings
New York
- Broome Oncology - Johnson City
Pennsylvania
- Guthrie Medical Group Sayre - Sayre
Aichi-ken
- Local Institution - 0017 - Nagoya
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2017-06-02 |
| Est. Completion | 2022-03-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03090737
The ClinicalTrials.gov registry entry for NCT03090737 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (80% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Nivolumab is the first listed.
NCT03090737 reports 17 study locations spanning 13 distinct geographic areas - top geographies include Ontario, Other, Alabama.
Frequently Asked Questions
What is clinical trial NCT03090737 about?
NCT03090737 is a clinical study titled "Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer". A study to evaluate the safety of Nivolumab in participants with advanced or metastatic non-small cell lung cancer
What is the current status of trial NCT03090737?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2017-06-02. Estimated completion is 2022-03-14.
What conditions does trial NCT03090737 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT03090737?
The interventions under investigation include: Nivolumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03090737?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03090737 being conducted?
This trial has 17 study locations across Alabama, California, Montana, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.